Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVGBM vaccine dose-finding and safety in surgically resected glioblastoma or astrocytoma
2022-501423-25-00Phase 2Completed
- Sponsor
- CureVac
- Start
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2 trial of CVGBM in glioblastoma (GBM) and astrocytoma, sponsored by CureVac. Started Mar 2023; status: completed.
02
Drugs
CVGBM
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on 2022-501423-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501423-25-00.